Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus.
Oncolytic adenoviruses are anticancer agents that replicate within tumors and spread to uninfected tumor cells, amplifying the anticancer effect of initial transduction. We tested whether coating the viral particle with polyethylene glycol (PEG) could reduce transduction of hepatocytes and hepatotoxicity after systemic (intravenous) administration of oncolytic adenovirus serotype 5 (Ad5). Conjugating Ad5 with high molecular weight 20-kDa PEG but not with 5-kDa PEG reduced hepatocyte transduction and hepatotoxicity after intravenous injection. PEGylation with 20-kDa PEG was as efficient at detargeting adenovirus from Kupffer cells and hepatocytes as virus predosing and warfarin. Bioluminescence imaging of virus distribution in two xenograft tumor models in nude mice demonstrated that PEGylation with 20-kDa PEG reduced liver infection 19- to 90-fold. Tumor transduction levels were similar for vectors PEGylated with 20-kDa PEG and unPEGylated vectors. Anticancer efficacy after a single intravenous injection was retained at the level of unmodified vector in large established prostate carcinoma xenografts, resulting in complete elimination of tumors in all animals and long-term tumor-free survival. Anticancer efficacy after a single intravenous injection was increased in large established hepatocellular carcinoma xenografts, resulting in significant prolongation of survival as compared with unmodified vector. The increase in efficacy was comparable to that obtained with predosing and warfarin pretreatment, significantly extending the median of survival. Shielding adenovirus with 20-kDa PEG may be a useful approach to improve the therapeutic window of oncolytic adenovirus after systemic delivery to primary and metastatic tumor sites.
Doronin
Konstantin
K
Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55902, USA.
Shashkova
Elena V
EV
May
Shannon M
SM
Hofherr
Sean E
SE
Barry
Michael A
MA
D000256:Adenoviridae / Q000737:chemistry* / Q000235:genetics / Q000502:physiology*; D000818:Animals; D002277:Carcinoma / Q000628:therapy; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000628:therapy*; D045744:Cell Line, Tumor; D005260:Female; D005822:Genetic Vectors / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry* / Q000502:physiology; D049452:Green Fluorescent Proteins / Q000235:genetics / Q000378:metabolism; D022781:Hepatocytes / Q000821:virology*; D006801:Humans; D007275:Injections, Intravenous; D008113:Liver Neoplasms / Q000401:mortality / Q000628:therapy*; D008156:Luciferases / Q000235:genetics / Q000378:metabolism; D008297:Male; D051379:Mice; D008819:Mice, Nude; D050130:Oncolytic Virotherapy / Q000379:methods*; D011092:Polyethylene Glycols / Q000737:chemistry* / Q000494:pharmacology; D011471:Prostatic Neoplasms / Q000628:therapy; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism; D014161:Transduction, Genetic; D016896:Treatment Outcome
D011993:Recombinant Fusion Proteins; D049452:Green Fluorescent Proteins; D011092:Polyethylene Glycols; D008156:Luciferases